Akebia Therapeutics, Inc. (AKBA)
USD 1.76
(-5.88%)
USD 1.76
(-5.88%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 194.62 Million | 292.6 Million | 213.57 Million | 295.3 Million | 335 Million | 207.74 Million |
| Cost of Revenue | 74.14 Million | 84.79 Million | 153.39 Million | 295.9 Million | 145.33 Million | 7.68 Million |
| Gross Profit | 120.47 Million | 207.8 Million | 60.18 Million | -601 Thousand | 189.66 Million | 200.05 Million |
| Operating Expenses | 201.11 Million | 270.98 Million | 325.5 Million | 375.84 Million | 475.95 Million | 378.19 Million |
| Selling, General and Administrative Expenses | 100.23 Million | 141.87 Million | 174.16 Million | 153.94 Million | 149.45 Million | 87.06 Million |
| Research and Development Expenses | 63.07 Million | 129.11 Million | 147.85 Million | 218.48 Million | 322.96 Million | 291.06 Million |
| Other Expenses | 3.41 Million | -12.54 Million | 3.48 Million | 3.4 Million | 3.52 Million | 6.23 Million |
| Cost and Expenses | 240.87 Million | 355.78 Million | 478.89 Million | 671.74 Million | 621.28 Million | 385.88 Million |
| Operating Income | -46.25 Million | -63.18 Million | -265.31 Million | -376.44 Million | -286.28 Million | -178.13 Million |
| Interest Expense | 6.03 Million | 15.68 Million | 19.93 Million | 8.87 Million | 1.4 Million | 6.15 Million |
| Income Tax Expense | - | 13.44 Million | -37.97 Million | -33.59 Million | -6.63 Million | -28.33 Million |
| Earnings before Tax | -51.92 Million | -92.56 Million | -282.84 Million | -383.45 Million | -286.29 Million | -171.9 Million |
| Net Income | -51.92 Million | -106 Million | -244.87 Million | -349.86 Million | -279.65 Million | -171.9 Million |
| Earnings Per Share Basic | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 |
| Earnings Per Share Diluted | -0.28 | -0.58 | -1.48 | -2.53 | -2.36 | -1.47 |
| Weighted Average Shares Outstanding | 187.46 Million | 182.78 Million | 165.94 Million | 138.46 Million | 118.39 Million | 116.88 Million |
| Weighted Average Shares Outstanding (Diluted) | 187.46 Million | 182.78 Million | 165.94 Million | 138.46 Million | 118.39 Million | 116.88 Million |
| Gross Margin | 0.62 | 0.71 | 0.28 | -0.00 | 0.57 | 0.96 |
| EBIT Margin | -0.04 | -0.16 | -1.24 | -1.27 | -0.85 | -0.86 |
| Profit Margin | -0.27 | -0.36 | -1.15 | -1.18 | -0.83 | -0.83 |
| EBITDA | -6.86 Million | -43.25 Million | -225.96 Million | -340.99 Million | -247.64 Million | -178.09 Million |
| Earnings Before Tax Margin | -0.24 | -0.22 | -1.24 | -1.27 | -0.85 | -0.86 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 43.64 Million | 32.6 Million | 56.19 Million | 194.62 Million | 42.04 Million | 56.37 Million |
| Cost of Revenue | 17.44 Million | 11.96 Million | 19.06 Million | 75.73 Million | 18 Million | 17.28 Million |
| Gross Profit | 26.2 Million | 20.63 Million | 37.13 Million | 118.88 Million | 24.03 Million | 39.09 Million |
| Operating Expenses | 34.92 Million | 35.51 Million | 35.76 Million | 164.96 Million | 36.9 Million | 48.18 Million |
| Selling, General and Administrative Expenses | 27.67 Million | 26.14 Million | 26.29 Million | - | 22.71 Million | 27.03 Million |
| Research and Development Expenses | 7.24 Million | 9.36 Million | 9.47 Million | - | 13.33 Million | 20.19 Million |
| Other Expenses | -39 Thousand | 95 Thousand | 658 Thousand | 887 Thousand | -43 Thousand | -1.65 Million |
| Cost and Expenses | 52.37 Million | 47.48 Million | 54.82 Million | 240.69 Million | 54.91 Million | 65.46 Million |
| Operating Income | -8.72 Million | -14.87 Million | 1.37 Million | -46.07 Million | -13.03 Million | -8.99 Million |
| Interest Expense | 2.14 Million | 2.49 Million | 1.41 Million | 6.03 Million | 1.41 Million | -1.64 Million |
| Income Tax Expense | - | 9.33 Million | -1000.00 | 41.67 Million | 1.36 Million | 94 Thousand |
| Earnings before Tax | -8.58 Million | -17.98 Million | 613 Thousand | -51.92 Million | -14.48 Million | -11.17 Million |
| Net Income | -8.58 Million | -17.98 Million | 614 Thousand | -51.92 Million | -14.48 Million | -11.17 Million |
| Earnings Per Share Basic | -0.04 | -0.09 | 0.00 | - | -0.08 | -0.06 |
| Earnings Per Share Diluted | -0.04 | -0.09 | 0.00 | - | -0.08 | -0.06 |
| Weighted Average Shares Outstanding | 209.7 Million | 204.95 Million | 189.9 Million | 187.46 Million | 188.3 Million | 186.81 Million |
| Weighted Average Shares Outstanding (Diluted) | 209.7 Million | 204.95 Million | 190.49 Million | 187.46 Million | 188.3 Million | 186.81 Million |
| Gross Margin | 0.60 | 0.63 | 0.66 | 0.61 | 0.57 | 0.69 |
| EBIT Margin | 0.02 | -0.17 | 0.19 | - | -0.08 | -0.15 |
| Profit Margin | -0.20 | -0.55 | 0.01 | -0.27 | -0.34 | -0.20 |
| EBITDA | 685 Thousand | -5.5 Million | 10.77 Million | - | -3.5 Million | -8.66 Million |
| Earnings Before Tax Margin | -0.20 | -0.46 | 0.02 | -0.24 | -0.31 | -0.16 |
ALJXR
POAHY
3936
0LJB
AOLS
GENO